Paediatric Respiratory Clinician, Wal-yan Respiratory Research Centre
| Role | Organisation | Sources |
|---|---|---|
| Founder and Director | Respirion | Brandon Capital, Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Paediatric Respiratory Clinician | Wal-yan Respiratory Research Centre | Brandon Capital, Brandon BioCatalyst |
| Respiratory Physician (former) | Perth Children's Hospital | Brandon Capital, Brandon Capital portfolio |
Stories naming Dr Barry Clements. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.
WA's Innovation Seed Fund has awarded almost $5 million in grants to 12 researchers and startups for health projects, from liver cancer tests to endometriosis diagnosis, ranging from $90,000 to $500,000.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.
The MRCF Biomedical Translation Fund has launched Respirion Pharmaceuticals, a Perth biotech developing an inhaled antibiotic for cystic fibrosis, committing up to A$20 million, with up to US$3 million from the CF Foundation.